Lexicon Pharmaceuticals (LXRX) Shares Outstanding (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Shares Outstanding (Entity) for 17 consecutive years, with $425.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 16.45% year-over-year to $425.7 million; the TTM figure through Mar 2026 stood at $425.7 million (up 16.45% YoY), while the FY2025 annual figure was $365.8 million, up 0.78% from the prior year.
• Shares Outstanding (Entity) improved to $425.7 million in Q1 2026 per LXRX's latest filing, from $365.8 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $425.7 million in Q1 2026 and bottomed at $150.1 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $281.8 million across 5 years, with a median of $247.8 million in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 77.27% — and 2025, when it rose 0.76%.
• Lexicon Pharmaceuticals' Shares Outstanding (Entity) stood at $189.2 million in 2022, then gained by 29.9% to $245.8 million in 2023, then soared by 47.69% to $363.0 million in 2024, then increased by 0.78% to $365.8 million in 2025, then increased by 16.36% to $425.7 million in 2026.
• Business Quant data shows LXRX's Shares Outstanding (Entity) at $425.7 million in Q1 2026, $365.8 million in Q4 2025, and $365.8 million in Q3 2025.